Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 15;25(4):420-424.
doi: 10.7499/j.issn.1008-8830.2211052.

[Research progress of nervous system damage in Pompe disease]

[Article in Chinese]
Wen-Chao Zhang  1 , Ying-Ying Mao  1 , Qian Chen  1
Affiliations
Review

[Research progress of nervous system damage in Pompe disease]

[Article in Chinese]
Wen-Chao Zhang et al. Zhongguo Dang Dai Er Ke Za Zhi. .

Abstract
in English, Chinese

Pompe disease, also known as glycogen storage disease type Ⅱ, is a rare autosomal recessive disease. With the application of enzyme replacement therapy, more and more patients with Pompe disease can survive to adulthood, and nervous system-related clinical manifestations gradually emerge. Nervous system involvement seriously affects the quality of life of patients with Pompe disease, and a systematic understanding of the clinical manifestations, imaging features and pathological changes of nervous system injury in Pompe disease is of great significance for the early identification and intervention of Pompe disease. This article reviews the research progress of neurological damage in Pompe disease.

庞贝病（Pompe disease）亦称糖原贮积病Ⅱ型，是常染色体隐性遗传的罕见病，随着酶替代疗法的应用，越来越多的庞贝病患者可存活至成年，以往未曾观察到的神经系统相关临床表现逐渐显现。神经系统受累严重影响庞贝病患者的生活质量，系统了解庞贝病神经系统损伤的病理变化、临床表现、影像学表现，对庞贝病的早期识别、早期干预有重要意义。该文就庞贝病神经系统损伤的研究进展进行综述。.

Keywords: Clinical manifestation; GAA gene; Glycogen storage disease type Ⅱ; Nervous system; Pompe disease.

PubMed Disclaimer

Conflict of interest statement

所有作者均声明不存在利益冲突。

References

    1. Ebbink BJ, Poelman E, Aarsen FK, et al. . Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain[J]. Dev Med Child Neurol, 2018, 60(6): 579-586. DOI: 10.1111/dmcn.13740. - DOI - PubMed
    1. Spiridigliozzi GA, Keeling LA, Stefanescu M, et al. . Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up[J]. Mol Genet Metab, 2017, 121(2): 127-137. DOI: 10.1016/j.ymgme.2017.04.014. - DOI - PMC - PubMed
    1. van den Dorpel JJA, van der Vlugt WMC, Dremmen MHG, et al. . Is the brain involved in patients with late-onset Pompe disease?[J]. J Inherit Metab Dis, 2022, 45(3): 493-501. DOI: 10.1002/jimd.12469. - DOI - PMC - PubMed
    1. Ebbink BJ, Poelman E, Plug I, et al. . Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge[J]. Neurology, 2016, 86(13): 1260-1261. DOI: 10.1212/WNL.0000000000002523. - DOI - PubMed
    1. Korlimarla A, Spiridigliozzi GA, Stefanescu M, et al. . Behavioral, social and school functioning in children with Pompe disease[J]. Mol Genet Metab Rep, 2020, 25: 100635. DOI: 10.1016/j.ymgmr.2020.100635. - DOI - PMC - PubMed

Substances